

Appendix I: Box 22 - Dummy baseline table for the TAPPS trial

Characteristic	Full population (cutaneous and non-cutaneous)		Subpopulation (cutaneous)	
	TRC105 and Pazopanib (n=xx)	Pazopanid alone (n=xx)	TRC105 and Pazopanib (n=xx)	Pazopanid (n=xx)
Age, years				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
Sex, n(%)				
Female	xx(xx%)	xx(xx%)	xx(xx%)	xx(xx%)
Male	xx(xx%)	xx(xx%)	xx(xx%)	xx(xx%)
Height, m				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
Weight, Kg				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xxx)	xx(xxx)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
Plasma Levels:				
VEGF ¹				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
sVEGFR2 ²				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
sCD105 ³				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
PIGF ⁴				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx
CTCs ⁵				
Mean(SD)	xx(xx.x)	xx(xx.x)	xx(xx.x)	xx(xx.x)
Min, max	xx, xx	xx, xx	xx, xx	xx, xx

¹ vascular endothelial growth factor; ² soluble vascular endothelial growth receptor; ³ soluble endoglin; ⁴ placental growth factor; ⁵ numbers of endoglin expressing circulating tumor cells; min, minimum; max, maximum; SD, standard deviation, Kg, kilograms; m, metres